Journey Medical Corporation (NasdaqCM: DERM)
Health Care · Pharmaceuticals · US
$7.53
-2.84% today · +4.7% 1Y
Journey Medical Corporation (NasdaqCM: DERM) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $218.74M and employs 58 people.
Over the last twelve months the share price has gained 4.7%, trading between 4.31 and 9.56.
Tweenvest scores Journey Medical Corporation across four factors: quality 50/100, value 63/100, growth 65/100. Its strongest factor is growth.
DERM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $218.74M
- Revenue (TTM)
- $68.18M
- P/E
- —
- EPS
- -0.23
- Dividend yield
- —
- Beta (5Y)
- 1.08
- 52-week high
- $9.56
- 52-week low
- $4.31
- Avg volume (3M)
- —
- Shares outstanding
- 28.22M
- Employees
- 58
- Next earnings
- —
About Journey Medical Corporation
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
- ISIN
- US48115J1097
- Founded
- 2014
- Listed since
- Nov 12, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.